Updates to Reimbursement Rates and Coverage for Long-Acting Injectable Buprenorphine for Substance Use Disorders
Maryland Medicaid expanded coverage for long-acting injectable buprenorphine (Brixadi, Sublocade, Vivitrol) to include Physicians, Nurse Practitioners, and Physician Assistants, effective March 1, 2026. Reimbursement rates have been updated for all three medications, and providers must have current DEA registration to bill. BHASO will only reimburse when drugs are purchased from manufacturer and administered directly by the provider—not when prescribed only or obtained from pharmacy.